Vorinostat is an HDAC inhibitor that is currently approved for use in treating cutaneous T cell lymphoma (CTCL). It is being studied for use in several other indications.
| SparkCures ID | 72 |
|---|---|
| Developed By | Merck Sharp & Dohme Corp. |
| Generic Name | Vorinostat |
| Additional Names | Zolinza, MK0683 |
| Treatment Classifications |
There are no resources, links or videos to display for this treatment.